Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Verweij

Showing results (121-130 of 234) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Medicinal cannabis in oncology practice: still a bridge too far?Floris A de Jong, Frederike K Engels, Ron H J Mathijssen, et al.
Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2008
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylateRaf Sciot, Maria Debiec-Rychter, Soren Daugaard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderlyAlbert J ten Tije, Jaap Verweij, Michael A Carducci, et al.
Journal of Clinical Pharmacology|May 24, 2011
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunctionGaia Schiavon, Karel Eechoute, Ron H J Mathijssen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEmma Guttman-Yassky, Alain Mita, Maja De Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute, Alex Sparreboom, Herman Burger, et al.
Clinical Pharmacology and Therapeutics|April 30, 2004
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelFrederike K Engels, Albert J Ten Tije, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancerMarco B Polee, Alex Sparreboom, Ferry A L M Eskens, et al.
Journal of the National Cancer Institute|December 7, 2006
Pharmacogenetics of ABCG2 and adverse reactions to gefitinibGeorge Cusatis, Vanesa Gregorc, Jing Li, et al.
Pageof 24

Showing results (121-130 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2005
Medicinal cannabis in oncology practice: still a bridge too far?Floris A de Jong, Frederike K Engels, Ron H J Mathijssen, et al.
Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 26, 2008
Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylateRaf Sciot, Maria Debiec-Rychter, Soren Daugaard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderlyAlbert J ten Tije, Jaap Verweij, Michael A Carducci, et al.
Journal of Clinical Pharmacology|May 24, 2011
Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunctionGaia Schiavon, Karel Eechoute, Ron H J Mathijssen, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEmma Guttman-Yassky, Alain Mita, Maja De Jonge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute, Alex Sparreboom, Herman Burger, et al.
Clinical Pharmacology and Therapeutics|April 30, 2004
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelFrederike K Engels, Albert J Ten Tije, Sharyn D Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancerMarco B Polee, Alex Sparreboom, Ferry A L M Eskens, et al.
Journal of the National Cancer Institute|December 7, 2006
Pharmacogenetics of ABCG2 and adverse reactions to gefitinibGeorge Cusatis, Vanesa Gregorc, Jing Li, et al.
Pageof 24